Gabapentin Capsule
Product Images NDC 68788-8816

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules Usp 400mg Cv (Gabapentin 400mg 100s)

Label for Gabapentin Capsules USP 400 mg (CV), a generic form of Neurontin, manufactured by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, a barcode, and dosage directions in English and Spanish. It specifies oral capsule dosage form with each capsule containing 400 mg Gabapentin.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over 8 weeks comparing Gabapentin 3600 mg/day and placebo. The x-axis represents weeks with phases for 4-week dose titration and 4-week fixed dose periods, while the y-axis shows mean pain scores from 0 to 10. Gabapentin scores decrease steadily, while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph displaying mean pain scores over 7 weeks, comparing placebo and two Gabapentin dosage groups (1800 mg/day and 2400 mg/day). The x-axis shows weeks from baseline to week 7; the y-axis shows mean pain scores from 0 to 10. The graph is divided into a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. The y-axis represents percentage from 0% to 100%. Study 1 compares placebo (PBO) at 12% to Gabapentin 3600 mg at 29%. Study 2 compares placebo (PBO) at 14% to Gabapentin 1800 mg at 32% and Gabapentin 2400 mg at 34%. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a gender adjustment factor. The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and multiplies by 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin, showing its molecular arrangement including a cyclohexane ring and attached functional groups with amine and carboxylic acid groups clearly depicted.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart depicting the percentage difference on the vertical axis against daily dose in mg on the horizontal axis for Gabapentin. The chart includes data points from three studies labeled as Study a, Study b, and Study c, shown with black, gray, and white squares respectively, illustrating variability in difference percentages at doses of approximately 600, 900, 1200, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.